Ginkgo Bioworks Holdings (DNA) Total Liabilities (2019 - 2026)
Ginkgo Bioworks Holdings posted quarterly Total Liabilities of $589.9 million for Q1 2026, down 8.69% year-on-year from $646.0 million in Q1 2025, and down 3.47% on a QoQ basis from $611.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 8 years of Total Liabilities data on file, last reported at $589.9 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities fell 8.69% year-over-year to $589.9 million; the trailing twelve-month figure through Mar 2026 stood at $589.9 million (down 8.69% YoY), and the FY2025 full-year result was $611.1 million, down 7.6% from the prior year.
- Total Liabilities for Q1 2026 stood at $589.9 million, down from $611.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $809.6 million in Q1 2023 and bottomed at $427.2 million in Q2 2022.
- The 5-year median for Total Liabilities is $629.4 million (2025), against an average of $639.4 million.
- The widest annual swing landed in 2022, when Total Liabilities soared 195.51%; it then decreased 29.25% in 2023.
- A 5-year view of Total Liabilities shows it stood at $803.0 million in 2022, then fell by 29.25% to $568.2 million in 2023, then climbed by 16.4% to $661.4 million in 2024, then decreased by 7.6% to $611.1 million in 2025, then retreated by 3.47% to $589.9 million in 2026.
- The last three Total Liabilities figures came in at $589.9 million (Q1 2026), $611.1 million (Q4 2025), and $629.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | 589.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 589.92 Mn |
| Dec 31, 2025 | 611.11 Mn |
| Sep 30, 2025 | 629.38 Mn |
| Jun 30, 2025 | 618.06 Mn |
| Mar 31, 2025 | 646.04 Mn |
| Dec 31, 2024 | 661.39 Mn |
| Sep 30, 2024 | 682.94 Mn |
| Jun 30, 2024 | 792.18 Mn |
| Mar 31, 2024 | 594.49 Mn |
| Dec 31, 2023 | 568.19 Mn |
| Sep 30, 2023 | 773.71 Mn |
| Jun 30, 2023 | 788.41 Mn |
| Mar 31, 2023 | 809.62 Mn |
| Dec 31, 2022 | 803.04 Mn |
| Sep 30, 2022 | 430.96 Mn |
| Jun 30, 2022 | 427.16 Mn |
| Mar 31, 2022 | 443.68 Mn |
| Dec 31, 2021 | 503.61 Mn |
| Sep 30, 2021 | 532.62 Mn |
| Jun 30, 2021 | 254.95 Mn |
| Mar 31, 2021 | 150.14 Mn |
| Dec 31, 2020 | 205.10 Mn |
| Sep 30, 2020 | -516.33 Mn |
| Dec 31, 2019 | -501.85 Mn |